Bispecific antibody molecular drugs are developed on the basis of monoclonal antibodies and are regarded as the second-generation antibody therapy for tumor treatment. Bispecific antibody molecules do not exist in the natural state and can only be prepared artificially. Its development is through the co-expression of two different H chains and two different L chains. Therefore, bispecific antibodies can specifically bind 2 different antigens.
The global Bispecific Antibody Molecular Drug market is projected to reach US$ 802.9 million in 2029, increasing from US$ 500 million in 2022, with the CAGR of 7.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bispecific Antibody Molecular Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Bispecific Antibody Molecular Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
MacroGenics
Xencor
Medimmune
Merrimsck
Merus NV
Genentech
Zhongshan Kangfang Biology Medicine
Sichuan Baili Pharmaceutical
Alphamab Oncology
Amgen
Segment by Type
EGFR×HER3 Target
PD-1×CTLA-4 Target
HER2×HER3 Target
Segment by Application
Pancreatic Cancer
Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Solid Tumor
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Bispecific Antibody Molecular Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Bispecific Antibody Molecular Drug Market Overview
1.1 Product Overview and Scope of Bispecific Antibody Molecular Drug
1.2 Bispecific Antibody Molecular Drug Segment by Type
1.2.1 Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2023-2029)
1.2.2 EGFR×HER3 Target
1.2.3 PD-1×CTLA-4 Target
1.2.4 HER2×HER3 Target
1.3 Bispecific Antibody Molecular Drug Segment by Application
1.3.1 Global Bispecific Antibody Molecular Drug Market Value by Application: (2023-2029)
1.3.2 Pancreatic Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Non-Small Cell Lung Cancer
1.3.6 Solid Tumor
1.3.7 Others
1.4 Global Bispecific Antibody Molecular Drug Market Size Estimates and Forecasts
1.4.1 Global Bispecific Antibody Molecular Drug Revenue 2018-2029
1.4.2 Global Bispecific Antibody Molecular Drug Sales 2018-2029
1.4.3 Global Bispecific Antibody Molecular Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bispecific Antibody Molecular Drug Market Competition by Manufacturers
2.1 Global Bispecific Antibody Molecular Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Bispecific Antibody Molecular Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Bispecific Antibody Molecular Drug Average Price by Manufacturers (2018-2023)
2.4 Global Bispecific Antibody Molecular Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Type & Application
2.7 Bispecific Antibody Molecular Drug Market Competitive Situation and Trends
2.7.1 Bispecific Antibody Molecular Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bispecific Antibody Molecular Drug Players Market Share by Revenue
2.7.3 Global Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bispecific Antibody Molecular Drug Retrospective Market Scenario by Region
3.1 Global Bispecific Antibody Molecular Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bispecific Antibody Molecular Drug Global Bispecific Antibody Molecular Drug Sales by Region: 2018-2029
3.2.1 Global Bispecific Antibody Molecular Drug Sales by Region: 2018-2023
3.2.2 Global Bispecific Antibody Molecular Drug Sales by Region: 2024-2029
3.3 Global Bispecific Antibody Molecular Drug Global Bispecific Antibody Molecular Drug Revenue by Region: 2018-2029
3.3.1 Global Bispecific Antibody Molecular Drug Revenue by Region: 2018-2023
3.3.2 Global Bispecific Antibody Molecular Drug Revenue by Region: 2024-2029
3.4 North America Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.4.1 North America Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.4.3 North America Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.5.1 Europe Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.5.3 Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.7.1 Latin America Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.7.3 Latin America Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bispecific Antibody Molecular Drug Sales by Type (2018-2029)
4.1.1 Global Bispecific Antibody Molecular Drug Sales by Type (2018-2023)
4.1.2 Global Bispecific Antibody Molecular Drug Sales by Type (2024-2029)
4.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
4.2 Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2029)
4.2.1 Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2023)
4.2.2 Global Bispecific Antibody Molecular Drug Revenue by Type (2024-2029)
4.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
4.3 Global Bispecific Antibody Molecular Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
5.1.1 Global Bispecific Antibody Molecular Drug Sales by Application (2018-2023)
5.1.2 Global Bispecific Antibody Molecular Drug Sales by Application (2024-2029)
5.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
5.2 Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
5.2.1 Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2023)
5.2.2 Global Bispecific Antibody Molecular Drug Revenue by Application (2024-2029)
5.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
5.3 Global Bispecific Antibody Molecular Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 MacroGenics
6.1.1 MacroGenics Corporation Information
6.1.2 MacroGenics Description and Business Overview
6.1.3 MacroGenics Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 MacroGenics Bispecific Antibody Molecular Drug Product Portfolio
6.1.5 MacroGenics Recent Developments/Updates
6.2 Xencor
6.2.1 Xencor Corporation Information
6.2.2 Xencor Description and Business Overview
6.2.3 Xencor Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Xencor Bispecific Antibody Molecular Drug Product Portfolio
6.2.5 Xencor Recent Developments/Updates
6.3 Medimmune
6.3.1 Medimmune Corporation Information
6.3.2 Medimmune Description and Business Overview
6.3.3 Medimmune Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Medimmune Bispecific Antibody Molecular Drug Product Portfolio
6.3.5 Medimmune Recent Developments/Updates
6.4 Merrimsck
6.4.1 Merrimsck Corporation Information
6.4.2 Merrimsck Description and Business Overview
6.4.3 Merrimsck Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merrimsck Bispecific Antibody Molecular Drug Product Portfolio
6.4.5 Merrimsck Recent Developments/Updates
6.5 Merus NV
6.5.1 Merus NV Corporation Information
6.5.2 Merus NV Description and Business Overview
6.5.3 Merus NV Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Merus NV Bispecific Antibody Molecular Drug Product Portfolio
6.5.5 Merus NV Recent Developments/Updates
6.6 Genentech
6.6.1 Genentech Corporation Information
6.6.2 Genentech Description and Business Overview
6.6.3 Genentech Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Genentech Bispecific Antibody Molecular Drug Product Portfolio
6.6.5 Genentech Recent Developments/Updates
6.7 Zhongshan Kangfang Biology Medicine
6.6.1 Zhongshan Kangfang Biology Medicine Corporation Information
6.6.2 Zhongshan Kangfang Biology Medicine Description and Business Overview
6.6.3 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolio
6.7.5 Zhongshan Kangfang Biology Medicine Recent Developments/Updates
6.8 Sichuan Baili Pharmaceutical
6.8.1 Sichuan Baili Pharmaceutical Corporation Information
6.8.2 Sichuan Baili Pharmaceutical Description and Business Overview
6.8.3 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolio
6.8.5 Sichuan Baili Pharmaceutical Recent Developments/Updates
6.9 Alphamab Oncology
6.9.1 Alphamab Oncology Corporation Information
6.9.2 Alphamab Oncology Description and Business Overview
6.9.3 Alphamab Oncology Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolio
6.9.5 Alphamab Oncology Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Amgen Bispecific Antibody Molecular Drug Product Portfolio
6.10.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bispecific Antibody Molecular Drug Industry Chain Analysis
7.2 Bispecific Antibody Molecular Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bispecific Antibody Molecular Drug Production Mode & Process
7.4 Bispecific Antibody Molecular Drug Sales and Marketing
7.4.1 Bispecific Antibody Molecular Drug Sales Channels
7.4.2 Bispecific Antibody Molecular Drug Distributors
7.5 Bispecific Antibody Molecular Drug Customers
8 Bispecific Antibody Molecular Drug Market Dynamics
8.1 Bispecific Antibody Molecular Drug Industry Trends
8.2 Bispecific Antibody Molecular Drug Market Drivers
8.3 Bispecific Antibody Molecular Drug Market Challenges
8.4 Bispecific Antibody Molecular Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
MacroGenics
Xencor
Medimmune
Merrimsck
Merus NV
Genentech
Zhongshan Kangfang Biology Medicine
Sichuan Baili Pharmaceutical
Alphamab Oncology
Amgen
*If Applicable.